Literature DB >> 3233202

Interaction of hirudin with thrombin: identification of a minimal binding domain of hirudin that inhibits clotting activity.

S J Mao1, M T Yates, T J Owen, J L Krstenansky.   

Abstract

Hirudin, isolated from the European leech Hirudo medicinalis, is a potent inhibitor of thrombin, forming an almost irreversible thrombin-hirudin complex. Previously, we have shown that the carboxyl terminus of hirudin (residues 45-65) inhibits clotting activity and without binding to the catalytic site of thrombin. In the present study, a series of peptides corresponding to this carboxyl-terminal region of hirudin have been synthesized, and their anticoagulant activity and binding properties to thrombin were examined. Binding was assessed by their ability to displace 125I-hirudin 45-65 from Sepharose-immobilized thrombin and by isolation of peptide-thrombin complexes. We show that the carboxyl-terminal 10 amino acid residues 56-65 (Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln) are minimally required for binding to thrombin and inhibition of clotting. Phe-56 was critical for maintaining anticoagulant activity as demonstrated by the loss of activity when Phe-56 was substituted with D-Phe, Glu, or Leu. In addition, we found that the binding of the carboxyl-terminal peptide of hirudin with thrombin was associated with a significant conformational change of thrombin as judged by circular dichroism. This conformational change might be responsible for the loss of clotting activity of thrombin.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3233202     DOI: 10.1021/bi00421a027

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  11 in total

1.  Inhibition of the amplification reactions of blood coagulation by site-specific inhibitors of alpha-thrombin.

Authors:  F A Ofosu; J W Fenton; J Maraganore; M A Blajchman; X Yang; L Smith; N Anvari; M R Buchanan; J Hirsh
Journal:  Biochem J       Date:  1992-05-01       Impact factor: 3.857

2.  Effect of Na+ binding on the conformation, stability and molecular recognition properties of thrombin.

Authors:  Vincenzo De Filippis; Elisa De Dea; Filippo Lucatello; Roberta Frasson
Journal:  Biochem J       Date:  2005-09-01       Impact factor: 3.857

Review 3.  Hirudin, a new therapeutic tool?

Authors:  J Bichler; H Fritz
Journal:  Ann Hematol       Date:  1991-08       Impact factor: 3.673

4.  Prediction of location of active sites in biologically active peptides.

Authors:  T Kikuchi
Journal:  J Protein Chem       Date:  1996-08

5.  The co-crystal structure of unliganded bovine alpha-thrombin and prethrombin-2: movement of the Tyr-Pro-Pro-Trp segment and active site residues upon ligand binding.

Authors:  M G Malkowski; P D Martin; J C Guzik; B F Edwards
Journal:  Protein Sci       Date:  1997-07       Impact factor: 6.725

6.  Evidence for common structural changes in thrombin induced by active-site or exosite binding.

Authors:  M A Parry; S R Stone; J Hofsteenge; M P Jackman
Journal:  Biochem J       Date:  1993-03-15       Impact factor: 3.857

7.  Crystal structure of two new bifunctional nonsubstrate type thrombin inhibitors complexed with human alpha-thrombin.

Authors:  J Féthière; Y Tsuda; R Coulombe; Y Konishi; M Cygler
Journal:  Protein Sci       Date:  1996-06       Impact factor: 6.725

8.  The isomorphous structures of prethrombin2, hirugen-, and PPACK-thrombin: changes accompanying activation and exosite binding to thrombin.

Authors:  J Vijayalakshmi; K P Padmanabhan; K G Mann; A Tulinsky
Journal:  Protein Sci       Date:  1994-12       Impact factor: 6.725

9.  Characterization of a membrane protease from rat submaxillary-gland mitochondria that possess thrombin-like activity.

Authors:  M Bharadwaj; D Bharadwaj; R N Hati
Journal:  Biochem J       Date:  1996-01-01       Impact factor: 3.857

10.  Thrombin-specific inhibition by and slow cleavage of hirulog-1.

Authors:  J I Witting; P Bourdon; D V Brezniak; J M Maraganore; J W Fenton
Journal:  Biochem J       Date:  1992-05-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.